COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

CEFOPERAZONE

SUMMARY REPORT (2)

1. Cefoperazone is a third generation semi-synthetic cephalosporin with a broad spectrum of activity against the majority of aerobic and anaerobic gram-positive and gram-negative pathogenic bacteria in vitro. Cefoperazone sodium and -dihydrate are used for intramammary treatment of clinical mastitis in lactating cattle. Dose levels used are 250 mg cefoperazone sodium per infected quarter once or 100 mg cefoperazone dihydrate per infected quarter twice with a dosing interval of 24 hours.

Currently cefoperazone is included in Annex III of Council Regulation (EEC) No 2377/90 in accordance with the following table:

<table>
<thead>
<tr>
<th>Pharmacologically active substance(s)</th>
<th>Marker residue</th>
<th>Animal species</th>
<th>MRLs</th>
<th>Target tissues</th>
<th>Other provisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefoperazone</td>
<td>Cefoperazone</td>
<td>Bovine</td>
<td>50 µg/kg</td>
<td>Milk</td>
<td>Provisional MRLs expire on 01.01.2001</td>
</tr>
</tbody>
</table>

and for bovine tissues other than milk cefoperazone is included in Annex II of Council Regulation (EEC) No 2377/90 as follows:

<table>
<thead>
<tr>
<th>Pharmacologically active substance(s)</th>
<th>Animal species</th>
<th>Other provisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefoperazone</td>
<td>Bovine</td>
<td>For intramammary use in lactating cows only and for all tissues except milk.</td>
</tr>
</tbody>
</table>

Further information has now been received in support of an entry of cefoperazone for bovine milk in Annex I of Council Regulation (EEC) No 2377/90.

2. Pharmacological studies with cefoperazone doses in the range of 250 to 6000 mg/kg bw administered intravenously or subcutaneously in mice, rats, rabbits, dogs and guinea pigs, elicited effects on several pharmacological parameters, such as central nervous system function, electroencephalogram, autonomic functions (respiration, cardiovascular system), haematological parameters, smooth muscle function, renal function, secretion of gastric juice and bile. Cefoperazone in general had effects comparable to those of other cephalosporins, but its cholinergic effects were minor. Because the extremely high doses at which these effects were found, the reported results had no consequence for the assessment of the ADI.
3. Plasma elimination half-life after parenteral administration in mouse, rat, rabbit, dog, monkey and man was 8 to 120 minutes. No significant differences were seen in plasma elimination half-life between intramuscular, intravenous, subcutaneous and intraperitoneal administration. Significant species differences occurred in protein binding (86 to 89% in human, monkey and rabbit versus 15 to 48% in dog, rat and mouse). Cefoperazone (radiolabelled and unlabelled) was distributed rapidly (within 15 minutes in mice) throughout the whole body with short-lived (less than 4 to 6 hours) high concentrations in liver and kidney and longer lasting (greater than 4 to 6 hours) high concentrations in urine and intestinal contents. Cefoperazone was hardly found in the central nervous system. Cefoperazone was eliminated quickly; within one day concentrations in tissues and organs were no longer detectable, with the exception of intestinal content and urine. Bioavailability was low (about 10%) after oral administration of 50 mg/kg bw in rats.

4. Cefoperazone was excreted via urine, faeces and bile. The excretion pattern differed between species. After parenteral administration, rats excreted the major part in bile (60 to 84% versus 14 to 39% in urine), while rabbits, dogs and monkeys excreted a larger part in urine (49 to 57%) than in bile (8 to 21%). After multiple dosage in rats of 50 mg/kg bw during 7 days, 100% was recovered in urine and faeces at two days after the last dosage. After oral administration in rats about 9% was excreted by bile, 2% by urinary route and about 96% was excreted with faeces.

5. Cefoperazone was little metabolised in mouse, rat, rabbit, dog, monkey and man. In the urine of mice, rats, rabbits, dogs and monkeys, no antibacterial components other than the parent compound were found. In urine and bile the metabolites T-1551-A and T-1551-F were found in small amounts (less than 5%). In faeces, the percentage of metabolites was higher. T-1551-F was present in 9% and 17% for rat and mouse, respectively. Furthermore, the metabolite T 1551-D was only present in faeces, 9% and 29% for rat and mouse, respectively. It was probably a product of hydrolysis by intestinal bacterial β-lactamases. This metabolite was shown virtually not to be absorbed after intraduodenal administration of the radiolabelled metabolite in rats.

6. Acute oral toxicity in rats and mice was low (LD₅₀ greater than 12 g/kg bw). Parenteral LD₅₀ values in these species were approximately 4 to 10 g/kg bw.

7. No oral repeated dose toxicity studies were available. Five repeated dose toxicity studies were carried out in rats: 1 month and 6 month subcutaneous studies with doses ranging from 125 to 2000 mg/kg bw, and 1, 3 and 6 month intraperitoneal studies with doses ranging from 500 to 4000 mg/kg bw. Adverse effects were observed at all examined dose levels. Effects found at the lowest dose levels were slight growth inhibition, increased fluidity of intestinal contents, caecum enlargement and occasional loose stools. Five repeated dose toxicity studies were carried out in dogs: a 35-day subcutaneous study with doses ranging from 250 to 1000 mg/kg bw, and 3-month and 6-month intramuscular studies with doses ranging from 100 to 500 mg/kg bw. Three intravenous toxicity studies of 1, 3 and 6 months were conducted with doses of 75 to 4000 mg/kg bw. For intravenously treated dogs, a NOEL of 75 mg/kg bw was retained.

In a 1-month intramuscular study in monkeys with doses of 0, 100, 200 and 400 mg/kg bw, mainly local tissue damage at the site of injection and haematological effects, probably related to this tissue damage, were found at doses of 200 and 400 mg/kg bw.

In general, toxicity found at repeated high parenteral doses in the different experiments included local injection site tissue damage, haemolytic anaemia and positive reaction in a haemagglutination test for antibodies (Coombs reaction) decreased thymus weight, nephrotoxicity and gastrointestinal effects. Caecum enlargement in rats was explained by the antibiotic effect on intestinal microflora.

8. No drug related effects on reproduction were found in a 2-generation reproduction study and a peri-/postnatal reproduction study in rats at subcutaneous doses of 125 to 1000 mg/kg bw.
9. No oral teratogenicity studies were available. Teratogenicity after intravenous administration was studied in rhesus monkeys (0, 50, 100, 400 mg/kg bw), mice (0, 125, 250, 500, 1000 mg/kg bw) and rats (0, 125, 250, 500, 1000 mg/kg bw). No teratogenic or foetotoxic effects were found in these experiments. Maternal toxicity was found at all examined dose levels in the rhesus monkeys (gastrointestinal effects, i.e. loose stools) and rats (caecal enlargement) and not at any dose level in the mouse study.

10. No mutagenicity of cefoperazone and its (separately tested) metabolites was observed in reverse gene mutation tests in *Escherichia coli* and *Salmonella typhimurium*, in a *Bacillus subtilis* recombination test and in an intramuscular *Salmonella typhimurium* host mediated assay in mice. An intravenous dominant lethal test in mice and an intravenous bone marrow cytogenetic test in male mice were also negative.

11. No carcinogenicity studies were provided. Since there was no indication from the repeated dose toxicity studies that cefoperazone causes preneoplastic lesions, the mutagenicity tests were negative and β-lactams in general are not mutagenic or carcinogenic, carcinogenicity data are not needed.

12. Immunotoxicity tests (rabbits, guinea pigs, mice, rats) showed that cefoperazone was hardly antigenic, alone or in combination with an adjuvant. Specific antibodies were formed in rabbit serum after intracutaneous injection with drug-bovine serum albumin coupled antigen (BSA); haemagglutination tests showed that their titer was lower than that of 2 other cephalosporins in the same experiment and that there was no cross-reactivity with other tested cephalosporins. Passive cutaneous anaphylaxis could be induced with cefoperazone-BSA complex in guinea pigs injected intracutaneously with rabbit anti-cefoperazone-BSA serum. This reaction was inhibited by cefoperazone but not some other tested cephalosporins. No antibody production was found in mice, no active or passive anaphylactic shock could be induced with intravenously administered cefoperazone in guinea-pigs, a weak Coombs’ reaction was found with human serum. From the provided data it can be concluded that cefoperazone is not more antigenic than other β-lactam antibiotics.

13. Repeated dose toxicity studies were provided following parenteral administration. Because of the low oral bioavailability of cefoperazone, it was acceptable to base the toxicological ADI on a NOEL from a parenteral study. The lowest intravenous dose in dogs in which no drug related effect was found was 75 mg/kg bw. A toxicological ADI of 0.75 mg/kg bw (i.e. 45 mg/person) can be calculated using this latter dose and applying a safety factor of 100.

14. In vitro MIC₅₀ values were available for ten relevant genera/species characteristic for the human gut flora at inoculum levels of 10⁶ and 10⁹ cfu/ml. The lowest MIC₅₀ values at these two densities were 0.031 and 0.063 µg/ml (both for *Bifidobacterium*) and the geometric mean MIC₅₀ values were 0.93 and 2.38 µg/ml (10th percentile: 0.85 µg/ml to cover the range of MIC₅₀ values). These data as well as those in available literature showed that at increasing bacterial density the MIC₅₀ values of cefoperazone increased and that an increase with at least a factor 2 of the MIC₅₀ found at 10⁹ cfu/ml could be expected at the density occurring in vivo. The effect of incubation under simulated intestinal conditions on the antimicrobial activity of cefoperazone against 3 strains of *Escherichia coli* was examined. Only a small decrease of activity was found under these conditions, at most with a factor 2. Available literature data indicated that resistance of bacteria against cefoperazone may be due to chromosomal as well as plasmidic mechanisms.

15. Inhibition of dairy starters by cefoperazone was examined at sub-MIC concentrations in 4 dairy starter cultures, selected from a range of 22 starter organisms for which the MIC values were determined in standard media and in milk. The effect of cefoperazone on total tritrable acidity, bacterial growth, clotting of milk and pH of the 4 selected starters incubated in milk were determined. The data showed that at concentrations of 250 µg/l and higher inhibitory effects on dairy organisms could be expected. However, the data were not suitable to derive a clear concentration without effect. Extrapolation of the relation between the effect on final pH and cefoperazone concentration resulted in an estimated concentration with negligible effect of 50 µg/l.
16. Literature on observations in humans was provided. Known side effects (after parenteral use of doses of 1 to 8 g per 12 hours) are skin rash, fever, diarrhoea, transient elevation of serum transaminases and transient eosinophilia. The general pattern of side effects of cefoperazone is similar to that of other cephalosporins, but intestinal effects like diarrhoea occur more frequently with cefoperazone than with other cephalosporins. The latter effect can be explained by its high excretion in bile and faeces and little metabolism resulting in effects on the intestinal flora.

17. The microbiological ADI was calculated as follows:

\[
\text{ADI} = \frac{\text{geometric mean MIC}_{50} \times \text{CF2}}{\text{CF1}} \times \frac{\text{fraction of an oral dose}}{\text{x weight of human (60 kg)}} \times \text{daily faecal bolus (150 ml)}
\]

Based on the above formula, the microbiological ADI can be calculated as follows:

\[
\text{ADI} = \frac{0.85 \times 4 \times 150}{3 \times 60} = 2.8 \ \mu g/\text{kg bw}\text{ i.e. } 170 \ \mu g/\text{person}
\]

The following assumptions were made:

- CF1 = 3 (the intermediate value between the values 1 and 5 for chromosomal and plasmidic resistance mechanisms);
- CF2 = 4 (a factor 2 to correct for inoculum density and a factor of 2 to correct for the effect of intestinal conditions on the microbiological activity of cefoperazone);
- 150 g was the weight of the daily faecal bolus;
- the fraction of an oral dose available for microorganisms was assumed to be 1;
- geometric mean MIC\(_{50}\) (10\(^{th}\) percentile) = 0.85 \(\mu g/ml\).

Since the microbiological ADI was lower than the toxicological ADI the microbiological ADI was established as the overall ADI.

18. In residue studies serum and urinary concentrations were measured. After intramammary administration of 250 mg cefoperazone as the sodium salt in 4 quarters of lactating cattle, low blood serum levels (0.03 to 0.68 \(\mu g/ml\), using a microbiological method with a detection limit of 0.02 \(\mu g/ml\)) were found around 8 to 9 hours after administration. In a 4-day period after administration about 10\% of the dose was excreted by urinary route.

19. A radiolabel residue study was provided in 28 lactating cattle, treated once with 250 mg \(^{14}\text{C-}\)cefoperazone per quarter. Four cows per time point were slaughtered at 12, 24, 72, 96 and 120 hours after administration and eight cows at 168 hours after administration. Total radioactivity in muscle, fat tissue, liver, kidney and mammary tissue was determined.

20. Cefoperazone concentrations were determined by HPLC-MS/MS (the proposed monitoring method). Mean total radioactive residues in tissues were 123 \(\mu g\) equivalents/kg in liver, 426 \(\mu g\) equivalents/kg in kidney, 24 \(\mu g\) equivalents/kg in muscle, 50 \(\mu g\) equivalents/kg in fat and 10 816 \(\mu g\) equivalents/kg in udder tissue at 12 hours post dose, and at 24 hours post dose 34 \(\mu g\) equivalents/kg in liver, 278 \(\mu g\) equivalents/kg in kidney, 9 \(\mu g\) equivalents/kg in muscle, 21 \(\mu g\) equivalents/kg in fat and 1 421 \(\mu g\) equivalents/kg in udder tissue. At later time points residue concentrations were lower. Ranges of cefoperazone concentrations were less than 42 to 145 \(\mu g/kg\) in liver, 165 to 320 \(\mu g/kg\) in kidney, less than 18 \(\mu g/kg\) (limit of quantification) in muscle and less than 16 \(\mu g/kg\) (limit of quantification) to 17 \(\mu g/kg\) in fat at 12 hours post dose, and at 24 hours post dose, less than 39 \(\mu g/kg\) (limit of quantification) to less than 61 \(\mu g/kg\) (liver), 33 to 73 \(\mu g/kg\) (kidney), much less than 18 \(\mu g/kg\) (limit of quantification) in muscle and less than 16 \(\mu g/kg\) (limit of quantification) in fat. At later time points only incidentally low detectable residue concentrations were found. Mean cefoperazone concentrations in udder tissue were 17 500 \(\mu g/kg\) at 12 hours and 1 890 \(\mu g/kg\) at 24 hours.
21. A radiolabel residue study was provided in 28 lactating cattle, treated once with 250 mg $^{14}$C-cefoperazone per quarter. Milk samples were collected up to 144 hours post dose. Concentrations of total radioactivity were measured at all milkings in all animals. At 12 hours post dose total residue concentrations were in the range of about 55 000 to 116 000 µg equivalents/kg, at 24 hours they were about 3000 to 30 000 µg equivalents/kg, thereafter they decreased to 6 to 204 µg equivalents/kg at 60 hours and less than 1 to 2 µg equivalents/kg at 144 hours. In general, concentrations in low yielding cows were higher than those in high yielding cows. Concentrations of the marker cefoperazone (HPLC-MS/MS, proposed monitoring method) were determined only up to 60 hours post dose in 4 low yielding and 4 high yielding cows. The limit of quantification was 17 µg/kg. At 12 hours post dose a range of about 62 000 to 138 000 µg/kg was found, at 24 hours 44 000 to 19 000 µg/kg, decreasing to less than the limit of quantification to 92 µg/kg at 60 hours post dose and less than the limit of quantification at 84 hours. The ratio of marker to total residue was variable, but high (up to 100%) during the first 4 milkings after administration. At the 5th milking (mean marker residue concentration about 30 µg/kg) it was 70%, and at later milkings it could not be determined due to too low marker residue concentrations.

22. A non-radiolabelled residue study was provided in which no concentrations of cefoperazone detectable with bioassays were found (less than 25 µg/kg) in liver, kidney, muscle and fat tissue of lactating cows slaughtered 1, 3 and 5 days after intramammary administration of 250 mg cefoperazone as the sodium salt in each quarter. In udder tissue only on the first day detectable concentrations (250 to 400 µg/kg) were found.

23. In milk the concentration in the first milking after intramammary administration of 250 mg non-radiolabelled cefoperazone as the sodium salt in each quarter as determined with bioassay methods was in the range 8000 to 330 000 µg/kg (the high value was found in a quarter producing 250 ml of milk). Hereafter, concentrations decreased to about 30 µg/kg at around the 5th to the 8th milking and to concentrations of 10 µg/kg at around the 7th to the 9th milking. Similar concentrations were found after 1 or 2 doses of 100 mg cefoperazone in all quarters as the dihydrate.

23. For monitoring of the marker residue cefoperazone in milk a validated HPLC-MS/MS method was provided. It was described in ISO 78/2 format. The limit of quantification was 10 µg/kg. The limit of detection was 1.65 µg/kg.

**Conclusions and recommendation**

Having considered:
- the microbiological ADI of 2.8 µg/kg bw (170 µg/person),
- the microbiological activity of the parent compound,
- the parent compound as the marker residue,
- the ratio of marker to total residues in milk being 70%,
- that compared to the ADI (170 µg/person) the maximum residue from edible tissues at 12 hours after administration (30 µg/person/day) was very low,
- that a validated analytical method for residues monitoring purposes in milk is available;

the Committee for Veterinary Medicinal Products recommends the inclusion of cefoperazone for bovine milk in Annex I of Council Regulation (EEC) No 2377/90 in accordance with the following table:

<table>
<thead>
<tr>
<th>Pharmacologically active substance(s)</th>
<th>Marker residue</th>
<th>Animal species</th>
<th>MRLs</th>
<th>Target tissues</th>
<th>Other provisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefoperazone</td>
<td>Cefoperazone</td>
<td>Bovine</td>
<td>50 µg/kg</td>
<td>Milk</td>
<td></td>
</tr>
</tbody>
</table>

Based on this MRL value for milk the maximum daily intake will represent 62% of the ADI.